Your browser doesn't support javascript.
loading
Rationale and design of the TACTICS registry: Optical coherence tomography guided primary percutaneous coronary intervention for patients with acute coronary syndrome.
Yamamoto, Myong Hwa; Kondo, Seita; Mizukami, Takuya; Yasuhara, Sakiko; Wakabayashi, Kohei; Kobayashi, Nobuaki; Sambe, Takehiko; Hibi, Kiyoshi; Nanasato, Mamoru; Sugiyama, Tomoyo; Kakuta, Tsunekazu; Kondo, Takeshi; Mitomo, Satoru; Nakamura, Sunao; Takano, Masamichi; Yonetsu, Taishi; Ashikaga, Takashi; Dohi, Tomotaka; Yamamoto, Hirosada; Kozuma, Ken; Yamashita, Jun; Yamaguchi, Junichi; Ohira, Hiroshi; Mitsumata, Kaneto; Namiki, Atsuo; Kimura, Shigeki; Honye, Junko; Kotoku, Nozomi; Higuma, Takumi; Natsumeda, Makoto; Ikari, Yuji; Sekimoto, Teruo; Mori, Hiroyoshi; Suzuki, Hiroshi; Otake, Hiromasa; Isomura, Naoei; Ochiai, Masahiko; Suwa, Satoru; Shinke, Toshiro.
Afiliação
  • Yamamoto MH; Division of Cardiology, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
  • Kondo S; Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Mizukami T; Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan; Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.
  • Yasuhara S; Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.
  • Wakabayashi K; Division of Cardiology, Cardiovascular Center, Showa University Koto-Toyosu Hospital Tokyo, Japan.
  • Kobayashi N; Department of Cardiology, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan.
  • Sambe T; Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan; Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.
  • Hibi K; Division of Cardiology, Yokohama City University Medical Center, Kanagawa, Japan.
  • Nanasato M; Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
  • Sugiyama T; Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.
  • Kakuta T; Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.
  • Kondo T; Department of Medicine, Hitachi Medical Center Hospital, Ibaraki, Japan.
  • Mitomo S; Department of Cardiovascular Medicine, New Tokyo Hospital, Chiba, Japan.
  • Nakamura S; Department of Cardiovascular Medicine, New Tokyo Hospital, Chiba, Japan.
  • Takano M; Department of Cardiology, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan.
  • Yonetsu T; Department of Interventional Cardiology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ashikaga T; Department of Cardiology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
  • Dohi T; Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Yamamoto H; Division of Cardiology, Teikyo University Hospital, Tokyo, Japan.
  • Kozuma K; Division of Cardiology, Teikyo University Hospital, Tokyo, Japan.
  • Yamashita J; Department of Cardiology, Tokyo Medical University Hospital, Tokyo, Japan.
  • Yamaguchi J; Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
  • Ohira H; Department of Cardiology, Edogawa Hospital, Tokyo, Japan.
  • Mitsumata K; Department of Cardiology, Ayase Heart Hospital, Tokyo, Japan.
  • Namiki A; Department of Cardiology, Kanto Rosai Hospital, Kanagawa, Japan.
  • Kimura S; Department of Cardiology, Yokohama Minami Kyosai Hospital, Kanagawa, Japan.
  • Honye J; Division of Cardiology, Kikuna Memorial Hospital, Kanagawa, Japan.
  • Kotoku N; Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
  • Higuma T; Division of Cardiology, Department of Internal Medicine, Kawasaki Municipal Tama Hospital, Kanagawa, Japan.
  • Natsumeda M; Department of Cardiology, Tokai University School of Medicine, Kanagawa, Japan.
  • Ikari Y; Department of Cardiology, Tokai University School of Medicine, Kanagawa, Japan.
  • Sekimoto T; Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan.
  • Mori H; Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan.
  • Suzuki H; Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan.
  • Otake H; Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Isomura N; Division of Cardiology, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
  • Ochiai M; Division of Cardiology, Showa University Northern Yokohama Hospital, Kanagawa, Japan.
  • Suwa S; Department of Cardiovascular Medicine, Juntendo University Shizuoka Hospital, Shizuoka, Japan.
  • Shinke T; Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. Electronic address: shinke@med.showa-u.ac.jp.
J Cardiol ; 80(6): 505-510, 2022 12.
Article em En | MEDLINE | ID: mdl-35907707
ABSTRACT

BACKGROUND:

Recent retrospective investigations have suggested that optical coherence tomography (OCT) enables the diagnosis of underlying acute coronary syndrome (ACS) causes such as plaque rupture, plaque erosion, and calcified nodule. The relationships of these etiologies with clinical outcomes, and the clinical utility of OCT-guided primary percutaneous coronary intervention (PCI) are not systematically studied in real-world ACS treatment settings.

METHODS:

The TACTICS registry is an investigator-initiated, prospective, multicenter, observational study to be conducted at 21 hospitals in Japan. A total of 700 patients with ACS (symptom onset within 24 h) undergoing OCT-guided primary PCI will be enrolled. The primary endpoint of the study is to identify the underlying causes of ACS using OCT-defined morphological assessment of the culprit lesion. The key secondary clinical endpoints are hazard ratios of the composite of cardiovascular death, non-fatal myocardial infarction, heart failure, or ischemia-driven revascularization in patients with underlying etiologies at the 12- and 24-month follow-ups. The feasibility of OCT-guided primary PCI for ACS will be assessed by the achievement rates of optimal post-procedural results and safety endpoints.

CONCLUSION:

The TACTICS registry will provide an overview of the underlying causes of ACS using OCT, and will reveal any difference in clinical outcomes depending on the underlying causes. The registry will also inform on the feasibility of OCT-guided primary PCI for patients with ACS.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Coronariana Aguda / Intervenção Coronária Percutânea Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Coronariana Aguda / Intervenção Coronária Percutânea Idioma: En Ano de publicação: 2022 Tipo de documento: Article